In addition, applications of PPARG agonist, rosiglitazone, as anticancer treatment in clinical trials was conducted in a pilot trial (19) and rosiglitazone was shown to reduce breast cancer risk in female patients with type 2 diabetes mellitus (33). Here, PPARG is linked to breast carcinoma.